Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 220

The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.

Sustained response and prevention of damage progression in patients with neonatal‐onset multisystem inflammatory disease treated with anakinra: A cohort study to determine three‐ and five‐year outcomes

Open access
Sibley, Cailin H., Plass, Nikki, Snow, Joseph, Wiggs, Edythe A., Brewer, Carmen C., King, Kelly A., Zalewski, Christopher, Kim, H. Jeffrey, Bishop, Rachel, Hill, Suvimol, Paul, Scott M., Kicker, Patrick, Phillips, Zachary, Dolan, Joseph G., Widemann, Brigitte, Jayaprakash, Nalini, Pucino, Frank, Stone, Deborah L., Chapelle, Dawn, Snyder, Christopher, Butman, John A., Wesley, Robert, Goldbach‐Mansky, Raphaela·2012·Arthritis & Rheumatism

Abstract

Objective: Blocking interleukin‐1 with anakinra in patients with the autoinflammatory syndrome neonatal‐onset multisystem inflammatory disease (NOMID) reduces systemic and organ‐specific inflammation. However, the impact of long‐term treatment has not been established. This study was undertaken to evaluate the long‐term effect of anakinra on clinical and laboratory outcomes and safety in patients with NOMID. Methods: We conducted a cohort study of 26 NOMID patients ages 0.80–42.17 years who were followed up at the NIH and treated with anakinra 1–5 mg/kg/day for at least 36 months. Disease activity was assessed using daily diaries, questionnaires, and C‐reactive protein level. Central nervous system (CNS) inflammation, hearing, vision, and safety were evaluated. Results: Sustained improvements in diary scores, parent's/patient's and physician's global scores of disease activity, parent's/patient's pain scores, and inflammatory markers were observed (all P < 0.001 at 36 and 60 months). At 36 and 60 months, CNS inflammation was suppressed, with decreased cerebrospinal fluid white blood cell counts (P = 0.0026 and P = 0.0076, respectively), albumin levels, and opening pressures (P = 0.0012 and P < 0.001, respectively). Most patients showed stable or improved hearing. Cochlear enhancement on magnetic resonance imaging correlated with continued hearing loss. Visual acuity and peripheral vision were stable. Low optic nerve size correlated with poor visual field. Bony lesions progressed. Adverse events other than viral infections were rare, and all patients continued to receive the medication. Conclusion: These findings indicate that anakinra provides sustained efficacy in the treatment of NOMID for up to 5 years, with the requirement of dose escalation. Damage progression in the CNS, ear, and eye, but not bone, is preventable. Anakinra is well tolerated overall.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/art.34409

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 220

Metadata

Authors
Sibley, C. H., Plass, N., Snow, J., Wiggs, E. A., Brewer, C. C., King, K. A., Zalewski, C., Kim, H. J., Bishop, R., Hill, S., Paul, S. M., Kicker, P., Phillips, Z., Dolan, J. G., Widemann, B., Jayaprakash, N., Pucino, F., Stone, D. L., Chapelle, D., Snyder, C., Butman, J. A., Wesley, R., & Goldbach‐Mansky, R.
Venue
Arthritis & Rheumatism
Publisher
Wiley
Published
2012-06-26
Volume
64
Issue
7
Pages
2375-2386
ISSN
  • 0004-3591 (ISSN-L)
  • 1529-0131
OpenAlex
W2036485405
Cited by
220
References
8
FWCI
8.48
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.